Praziquantel in the treatment of neurocysticercosis: long-term follow-up.
Thirty-five patients with active neurocysticercosis were treated with praziquantel and followed for 1 year after therapy. CT and CSF analysis showed that 91% of patients with parenchymal cysts improved, and 47% of patients with chronic arachnoiditis had remission. A single treatment with praziquantel for 2 weeks, administered in a daily dose of 50 mg/kg of body weight, was highly effective in parenchymal cysticercosis but less effective in meningeal cysticercosis. The benefits were sustained for at least 1 year.
D000293:Adolescent; D000328:Adult; D001100:Arachnoiditis / Q000188:drug therapy; D001927:Brain Diseases / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D003551:Cysticercosis / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003560:Cysts / Q000000981:diagnostic imaging / Q000188:drug therapy; D005500:Follow-Up Studies; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008581:Meningitis / Q000188:drug therapy; D008875:Middle Aged; D011223:Praziquantel / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D002556:Cerebrospinal Fluid Proteins; D007546:Isoquinolines; D011223:Praziquantel